Pfizer does not anticipate federal regulatory approval of ritlecitinib until at least 2023, according to the company’s December 2021 presentation to investors.
Pfizer does not anticipate federal regulatory approval of ritlecitinib until at least 2023, according to the company’s December 2021 presentation to investors.
(post is archived)